株式会社PRISM BioLab Logo

株式会社PRISM BioLab

Biotech firm developing small molecule drugs for 'undruggable' protein interactions.

206A | T

Overview

Corporate Details

ISIN(s):
JP3833190006
LEI:
Country:
Japan
Address:
藤沢市村岡東二丁目26番1号

Description

PRISM BioLab is a biotechnology company specializing in drug discovery and development. It utilizes its proprietary PepMetics® technology platform to create orally available, small molecule drugs that target protein-protein interactions (PPIs), which are often considered 'undruggable'. The platform designs molecules that mimic key peptide structures, such as α-helices and β-turns, to modulate these interactions. The company's primary mission is to develop novel therapeutics for intractable diseases that currently lack effective treatments. PRISM BioLab advances its pipeline through both internal research programs and strategic collaborations with pharmaceutical partners.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-12-24 07:31
確認書
Japanese ZIP 8.7 KB
2025-12-24 07:30
有価証券報告書-第14期(2024/10/01-2025/09/30)
Japanese ZIP 3.2 MB
2025-07-17 09:30
臨時報告書
Japanese ZIP 21.0 KB
2025-05-14 09:31
確認書
Japanese ZIP 8.7 KB
2025-05-14 09:30
半期報告書-第14期(2024/10/01-2025/09/30)
Japanese ZIP 224.7 KB
2024-12-27 07:34
内部統制報告書-第13期(2023/10/01-2024/09/30)
Japanese ZIP 22.2 KB
2024-12-27 07:33
確認書
Japanese ZIP 8.7 KB
2024-12-27 07:32
有価証券報告書-第13期(2023/10/01-2024/09/30)
Japanese ZIP 3.1 MB
2024-12-27 07:31
臨時報告書
Japanese ZIP 22.1 KB
2024-11-14 07:32
臨時報告書
Japanese ZIP 20.8 KB
2024-10-16 10:12
臨時報告書
Japanese ZIP 20.7 KB
2024-09-10 09:09
臨時報告書
Japanese ZIP 19.9 KB
2024-06-24 08:00
訂正有価証券届出書(新規公開時)
Japanese ZIP 2.2 MB
2024-06-14 08:00
訂正有価証券届出書(新規公開時)
Japanese ZIP 2.3 MB
2024-05-27 08:00
有価証券届出書(新規公開時)
Japanese ZIP 4.3 MB

Automate Your Workflow. Get a real-time feed of all 株式会社PRISM BioLab filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for 株式会社PRISM BioLab

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for 株式会社PRISM BioLab via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.